

Participant Flow:

Figure 1. Study CONSORT flow diagram (n= number of patients).




Table 1. Baseline demographics and clinical characteristics of patients entered into the two study groups: Patients were randomized to receive either sutures and a Tegaderm™ I.V. Advanced dressing (suture group) or a 3M™ PICC/CVC Securement system (consisting of 3M™ PICC/CVC Securement Device and a Tegaderm™ I.V. Advanced Dressing) (suture free group) to secure a short-term central venous catheter (CVC) onto the skin [*n*=number of patients or catheter days (IQR or %)].

	Suture group (<i>n</i>=86 patients)	Suture free group (<i>n</i>=85 patients)
Median age (in years) (IQR)	66 (56.3; 74)	62 (51; 72)
Number of males/ females (%)	59/27 (68.6/31.4)	68: 17 (80.0:20.0)
Median APACHE II score (IQR)	23 (15.5; 32)	21 (14; 29)
Median BMI (IQR)	26.7 (23.0; 31.9)(<i>n</i> =80)	26.8 (24.3; 30.5)(<i>n</i> =73)
Number of patients (%)receiving:		
Sedative agents	38 (44.2)	47 (55.3)
Paralysing agents	11 (12.8)	7 (8.2)
Endotracheal tube	43 (50.0)	50 (58.8)
Tracheostomy	7 (8.1)	16 (18.8)
Mechanical ventilation	46 (53.5)	55 (64.7)
Non-invasive ventilation	18 (20.9)	15 (17.6)
Haemodialysis	9 (10.5)	15 (17.6)
ECMO	2 (2.3)	2 (2.4)
<hr/>		
<i>n</i> = number of catheter days (%)		
RASS score	(<i>n</i>=494 catheter days)	(<i>n</i>=580 catheter days)
1 or above	30 (6.1)	33 (5.7)
0	227 (46.0)	249 (42.9)
-1 or less	237 (48.0)	298 (51.4)

APACHE II score = An acute physiology and chronic health evaluation score;

BMI = body mass index;

ECMO = Extracorporeal membrane oxygenation;

RASS score = The Richmond Agitation–Sedation Scale score.

Outcome Measures:

Table 1. Summary of study outcome.

<i>Primary endpoint:</i>	<i>Study outcome</i>
1. Total number of catheter dislodgements (displacement of CVC that leads to loss of functionality of the CVC).	No total catheter dislodgements or displacements occurred in either study group.

Adverse Events:

One adverse event was recorded in the suture free group, when a catheter became twisted. No harm was caused to the patient. There were no other adverse events associated with this trial.